INMUNE BIO INC
INMBNASDAQTrading Snapshot
- Day Range
- $1.93 – $1.98
- 52-Week Range
- $1.09 – $2.60
- Volume
- $2.80B
- Avg Volume
- $2.52B
- Shares Outstanding
- 26.6M
- Next Earnings
- Nov 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $50,000
- Last Q Revenue
- $12,132
- P/E Ratio
- -2.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.69
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +19.3%
Why Investors Own INMB
- ✓High-growth profile — revenue up +58.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INMUNE BIO INC
INMB
StockOtter · stockotter.spaceAbout INMUNE BIO INC
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept.
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment
INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market cap. Ebstrocel offers systemic itch reduction, differentiating it from c
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INmune Bio Q2 Earnings Call Highlights
INmune Bio NASDAQ: INMB outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrow